Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03829566
Other study ID # DIAD.ATTEND.2018
Secondary ID
Status Withdrawn
Phase Phase 2/Phase 3
First received
Last updated
Start date November 2019
Est. completion date November 28, 2025

Study information

Verified date November 2019
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.


Description:

The autologous stem cell transplant used in this research study is an investigational procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be causing your disease), rituximab (a biologic drug that targets B cells of your immune system), and intravenous immunoglobulin (IVIg) (pooled IgG antibodies from plasma donors with immunomodulatory and anti-inflammatory effects), followed by return of your own previously collected blood stem cells (autologous stem cell transplant). One day of plasmapheresis will also be performed the day prior to admission for stem cell transplant to remove disease-causing antibodies. The ability of this experimental treatment to stop relapses and progression (worsening) of your NMOSD will be assessed.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 28, 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age 18 - 65 years old at the time of pre-transplant evaluation

2. An established diagnosis of NMOSD (with or without aquaporin 4 (AQP4)-IgG antibody)

Exclusion Criteria:

1. Under age of 18 or over age of 65

2. Prisoners

3. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible, or any adult who is unable to consent (for adults cognitively impaired due to disease, consent may be obtained from the closest living relative).

4. Paraplegia or quadriplegia (must be able to use a walker if even for only a few feet)

5. Extensive subcortical white matter lesions

6. Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment

7. Myocardial infarction within the last 12 months. If longer than 12 months, must pass a dobutamine stress test and be cleared by cardiology.

8. Active systemic lupus erythematous, Sjogren's, myasthenia gravis, or another autoimmune disease

9. Sickle cell disease, sickle cell disease, or coagulopathy

10. Prior history of malignancy that required any radiotherapy, chemotherapy, or biological therapy

11. Positive pregnancy test, inability or unable to pursue effective means of birth control, or failure to willingly accept or comprehend irreversible sterility as a side effect of therapy

12. Women who are breastfeeding

13. Untreated life-threatening cardiac arrhythmia on electrocardiogram (EKG) or 24-hour holter

14. Left ventricular ejection fraction (LVEF) <50%

15. Tiffeneau-Pinelli index (FEV1/FVC) <70% of predicted after bronchodilator therapy (if necessary), or diffusing capacity of lung for carbon monoxide (DLCO) hemoglobin corrected <70 % predicted

16. Serum creatinine >2.0 mg/dl

17. Liver cirrhosis, transaminases >2x of normal limits, or bilirubin >2.0 mg/dl unless due to Gilbert's disease

18. Major hematological abnormalities such as platelet count < 100,000/µl or absolute neutrophil count (ANC) < 1000/µl

19. Active infection except asymptomatic bacteriuria

20. Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have magnetic resonance imaging (MRI) exams

21. Known hypersensitivity to mouse, rabbit, or E. coli derived proteins

22. Human immunodeficiency virus (HIV) positive

23. Hepatitis B or C positive

24. Use of natalizumab (Tysabri) within the previous six months

25. Use of fingolimod (Gilenya) within the previous three months

26. Use of dimethyl fumarate (Tecfidera) within the previous three months

27. Use of teriflunomide (Aubagio) unless cleared from the body (plasma concentration <0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days

28. Use of alemtuzumab (Lemtrada/Campath) within previous 12 months

29. Use of rituximab (Rituxan) or ocrelizumab (Ocrevus) within previous six months

30. Prior treatment with mitoxantrone (Novantrone)

Study Design


Intervention

Drug:
Rituximab
Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Cyclophosphamide
A medication used as chemotherapy and to suppress the immune system
Mesna
A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
rATG
A rabbit polyclonal antibody to lymphocytes
Methylprednisolone
A corticosteroid medication used to suppress the immune system and decrease inflammation
G-CSF
A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Biological:
IVIg
Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
Autologous Stem Cells
Infusion of patient's own stem cells

Locations

Country Name City State
United States Northwestern University Chicago Illinois
United States Northwestern University, Feinberg School of Medicine Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival Disease progression defined as: 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least six months apart and not due to a non-NMO disease process. The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. 5 years
Secondary Relapse-Free Survival Relapse defined as: Acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat, drugs or related pseudo-exacerbation. Supportive confirmation by enhancement on MRI is preferred but not mandatory. 5 years
Secondary Expanded Disability Status Scale (EDSS) Improvement The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Scripps Neurological Rating Scale (NRS) Improvement The NRS scale ranges from 0 to 100 in 1 point increments that represent lower levels of disability. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Improvement in Quality of Life Measured using the short form (SF)-36 health survey. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Paced Auditory Serial Addition Test (PASAT) Improvement The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Improvement measured with the 2" and 3" versions 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Ambulation Index Improvement The subject's walk of 25 feet is timed and a score from 0 to 10 is assigned based on their walk/gait and/or assistance required. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary 9 Hole Peg Test (9-HPT) Improvement The 9-HPT is a brief, standardized, quantitative test of upper extremity function. Both the dominant and non-dominant hands are tested twice, with the total time to complete the task each time recorded and then averaged. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Change in NMO IgG (aquaporin-4) Antibody Titer Evaluation of the antibody titer, looking for a change from positive to negative. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary Improvement in Visual Acuity A visual acuity test is an eye exam that checks how well one sees the details of a letter or symbol from a specific distance. 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
See also
  Status Clinical Trial Phase
Completed NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Recruiting NCT01024985 - Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct N/A
Recruiting NCT04601142 - Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT05573711 - Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Not yet recruiting NCT06118398 - Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05566769 - Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD N/A
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Recruiting NCT05356858 - An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients Phase 2
Recruiting NCT05982925 - Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Terminated NCT02398994 - A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Phase 3
Withdrawn NCT02087813 - Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Phase 1
Terminated NCT01339455 - Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Phase 1/Phase 2
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Active, not recruiting NCT04614454 - High Frequency Impulse Therapy for Neuropathic Pain in NMOSD Phase 2
Recruiting NCT03370965 - Optic Neuritis Differential Diagnosis Study N/A
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1
Recruiting NCT01623076 - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders